Industry News (Pathogen Inactivation)

Process for Donated Blood Involving Chemical Compounds Reported

Published in Blood Weekly, December 11th, 1995

Scientists from HemaSure Inc., Marlborough, Massachusetts, reported on the company's pathogen inactivation process for donated blood involving novel chemical compounds.

The presentation highlighted the safety and promising virus killing ability of the company's lead pathogen inactivation agents. The data were reported on October 25, 1995, by Hans J. Heiniger, D.V.M., Ph.D., Senior Vice President and Chief Scientific Officer of HemaSure, at the Blood Safety and Screening conference in Washington, D.C.

"The data reported by Dr. Heiniger represent HemaSure's substantial progress in advancing chemical inactivation technology for use in the SteriPath...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1995-12-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry